Holen Sie sich die Stockscreener-App
26.02
0.62%
0.16
Handel nachbörslich:
26.01
-0.010
-0.04%
Schlusskurs vom Vortag:
$25.86
Offen:
$25.19
24-Stunden-Volumen:
22,187
Relative Volume:
0.08
Marktkapitalisierung:
$34.90M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-24.14M
KGV:
-1.8606
EPS:
-13.985
Netto-Cashflow:
$-22.40M
1W Leistung:
-8.06%
1M Leistung:
-22.05%
6M Leistung:
+178.59%
1J Leistung:
+227.38%
1-Tages-Spanne:
$25.19
$27.92
1-Wochen-Bereich:
$25.02
$33.00
52-Wochen-Spanne:
$5.25
$36.76
Sensei Biotherapeutics Inc Stock (SNSE) Company Profile
Firmenname
Sensei Biotherapeutics Inc
Sektor
Branche
Telefon
(240) 243-8000
Adresse
1405 RESEARCH BLVD, SUITE 125, ROCKVILLE
Compare SNSE vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SNSE
Sensei Biotherapeutics Inc
|
26.02 | 34.68M | 0 | -24.14M | -22.40M | -13.98 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Sensei Biotherapeutics Inc Stock (SNSE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-20 | Eingeleitet | Leerink Partners | Outperform |
| 2025-06-02 | Fortgesetzt | H.C. Wainwright | Buy |
| 2024-05-14 | Eingeleitet | Stephens | Overweight |
| 2021-07-01 | Herabstufung | Berenberg | Buy → Hold |
| 2021-06-29 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-03-01 | Eingeleitet | Berenberg | Buy |
| 2021-03-01 | Eingeleitet | Citigroup | Buy |
| 2021-03-01 | Eingeleitet | Oppenheimer | Outperform |
| 2021-03-01 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Sensei Biotherapeutics Inc Aktie (SNSE) Neueste Nachrichten
Sensei Biotherapeutics Secures 200 Million Dollars for Oncology Pipeline - HarianBasis.co
Sensei Biotherapeutics (SNSE): Best Performing NASDAQ Stocks According to Wall Street Analysts - Insider Monkey
Sensei Biotherapeutics Doses First Patient in Phase 1b/2 Trial of PIKTOR in HR+/HER2- Advanced Breast Cancer - PharmiWeb.com
Sensei Biotherapeutics begins trial of PIKTOR in breast cancer By Investing.com - Investing.com Australia
Sensei Biotherapeutics begins trial of PIKTOR in breast cancer - Investing.com
10 Best Performing NASDAQ Stocks According to Wall Street Analysts - Insider Monkey
Short Selling Surges in Small-Cap Healthcare Stocks Amid Bearish Sentiment - GuruFocus
[144] Sensei Biotherapeutics, Inc. SEC Filing - Stock Titan
Sensei Biotherapeutics (SNSE) price target increased by 53.85% to 51.00 - MSN
Sensei Biotherapeutics (NASDAQ: SNSE) registers 24.87M resale shares - Stock Titan
[ARS] Sensei Biotherapeutics, Inc. SEC Filing - Stock Titan
Faeth-focused recapitalization at Sensei (NASDAQ: SNSE) reshapes ownership and adds $200M - Stock Titan
Sensei Biotherapeutics (SNSE) Stock: Risk vs Return Evaluation | Q4 2025: EPS Exceeds ExpectationsTrending Social Stocks - Newser
Is Sensei Biotherapeutics (SNSE) stock a favorable investment idea | Q4 2025: EPS Exceeds ExpectationsCrowd Breakout Signals - Xã Thanh Hà
Is Sensei Biotherapeutics (SNSE) stock facing investor skepticism | Q4 2025: Earnings Beat EstimatesHot Momentum Watchlist - Cổng thông tin điện tử tỉnh Lào Cai
Is Sensei Biotherapeutics (SNSE) stock relatively low risk (Market Focus) 2026-04-22High Beta Stocks - Xã Vĩnh Công
Sensei Biotherapeutics Inc Live Share Prices and Trades. SNSE.US Live Streaming Share Prices. - London South East
Leerink initiates Sensei Biotherapeutics stock at Outperform, $50 target By Investing.com - Investing.com South Africa
Leerink initiates Sensei Biotherapeutics stock at Outperform, $50 target - Investing.com
Sensei Biotherapeutics Announces Leadership and Board Transitions - The Globe and Mail
Sensei Biotherapeutics: If Proposals Are Approved, COO Anand Parikh Is Expected to Become CEO - Moomoo
Christopher W. Gerry, Thomas Ricks, and Kristian Humer Tender Conditional Resignations From Sensei Biotherapeutics Board, Effective in June - Moomoo
Leadership and board overhaul outlined by Sensei Biotherapeutics (NASDAQ: SNSE) - Stock Titan
Faeth deal shifts control; Sensei Biotherapeutics (NASDAQ: SNSE) seeks shareholder approvals - Stock Titan
Form 8-K/ACurrent report: [Amend] - ADVFN
Sensei Biotherapeutics (SNSE) details Faeth acquisition, PIPE and going-concern warning - Stock Titan
Sensei Biotherapeutics (SNSE) grants PFO 80,000 stock options - Stock Titan
Director at Sensei Biotherapeutics (SNSE) receives 23,100 stock options - Stock Titan
Sensei Biotherapeutics Inc and Faeth Therapeutics Acquisition Call Transcript - GuruFocus
Macro Review: Is Sensei Biotherapeutics Inc in a bullish channel2026 Trading Recap & Community Consensus Trade Signals - baoquankhu1.vn
Sensei Biotherapeutics Halts Lead Drug Development, Explores Sale Or Merger Options - MSN
Sensei Biotherapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference - BioSpace
Aug Update: What is the Moat Score of Sensei Biotherapeutics IncQuarterly Market Summary & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Should I Buy Sensei Biotherapeutics (SNSE) Stock Today | Price at $33.00, Up 6.38%Trend Signals - Newser
Investor Mood: What is the Moat Score of Sensei Biotherapeutics IncQuarterly Profit Summary & Safe Capital Growth Trade Ideas - baoquankhu1.vn
Sidley Represents Sensei Biotherapeutics in Acquisition of Faeth Therapeutics - Legal Desire Media and Insights
AI Stocks: Can Sensei Biotherapeutics Inc grow without dilution2026 Catalysts & Trade Opportunity Analysis Reports - baoquankhu1.vn
Sensei Biotherapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update - biospace.com
Sensei Biotherapeutics (SNSE) Sets Ambitious Clinical Goals for 2026 - GuruFocus
Faeth acquisition and $200M raise reshape Sensei Biotherapeutics (NASDAQ: SNSE) - stocktitan.net
Sensei Biotherapeutics Acquires Faeth, Advances PIKTOR Cancer Program with $200M Financing and Reports 2025 Financial Results - Minichart
Sensei Biotherapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Sensei Biotherapeutics Reports Full Year 2025 Financial Results And Provides Corporate Update - TradingView
Sensei Biotherapeutics (NASDAQ: SNSE) 2025 loss narrows, lands $200M - Stock Titan
Aug Chart Watch: What is Sensei Biotherapeutics Incs TAM Total Addressable Market2026 WrapUp & Real-Time Market Trend Scan - baoquankhu1.vn
If You Invested $1,000 in Sensei Biotherapeutics, Inc. (SNSE) - Stock Titan
Finanzdaten der Sensei Biotherapeutics Inc-Aktie (SNSE)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.77%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):